Biocompatible medical device coating using recombinant human albumin
Innovation in medical devices continues to create novel treatment options. However, medical device developers are facing challenges in ensuring safe and biocompatible products. Biocompatibility is crucial when using medical devices to ensure they do not elicit an adverse response by the patient.
Due to its natural propensities, albumin is widely utilized in the medical device industry for coating of stents and tubing, for instance in dialysis, to improve their biocompatibility.
Albumin's natural surface coating ability
Albumin has been demonstrated to cover both hydrophobic and hydrophilic surfaces in nearly a single molecule layer. This means that even small amounts of albumin can effectively cover large areas of surface. Using our recombinant human albumin (rAlb) products it has been shown that:
1-2 mg of albumin is sufficient to cover 1 m2 of surface
By coating with albumin, a biological interface is created, thereby limiting the exposure of the otherwise incompatible surface to the patient, increasing product safety.
The improved purity and defined nature of our rAlb product Recombumin® consistently produces the same surface coverage. This makes Recombumin especially suited to the medical devices industry as it minimizes the need for elaborate release procedures and product performance monitoring. Additionally, due to its recombinant nature, Recombumin is free of risk with respect to human derived pathogens and viruses, further warranting a safe product.
Learn more about recombinant human albumin for biocompatible surface coating and drug formulation by reading our whitepaper on formulation (Bookshelf).
Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. We partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with more than 80 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.